Ocata Therapeutics Inc (NASDAQ:OCAT)

Monday’s trading has closed, but OCAT is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 3:59pm ET
 -0.32 / -4.43%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ocata Therapeutics, Inc. is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.

Contact Information

Ocata Therapeutics, Inc.
33 Locke Drive
Marlborough Massachusetts 01752
P:(508) 756-1212
Investor Relations:



Individual stakeholders1.11%
Mutual fund holders--
Other institutional--

Top Executives

Paul K. WottonPresident, Chief Executive Officer & Director
Edward H. MylesChief Operating & Financial Officer
Robert P. LanzaChief Scientific Officer
Eddy AngladeExecutive Vice President-Clinical Development
Shi-Jiang LuSenior Director-Research

To view my watchlist

Not a member yet?

Sign up now for a free account